Learn More
OBJECTIVE We aimed to assess the role of zoledronic acid (ZOL) on the risk of fracture and bone mineral density (BMD) in women with osteoporosis. METHODS A double-blind and placebo-controlled design was taken in our study. 327 patients who received an intravenous 5-mg infusion zoledronic acid at day 0, at 12 months were enrolled in treatment group, and(More)
  • 1